Nothing Special   »   [go: up one dir, main page]

MX2012007234A - Nanocristales de monohidrato de calciprotiol. - Google Patents

Nanocristales de monohidrato de calciprotiol.

Info

Publication number
MX2012007234A
MX2012007234A MX2012007234A MX2012007234A MX2012007234A MX 2012007234 A MX2012007234 A MX 2012007234A MX 2012007234 A MX2012007234 A MX 2012007234A MX 2012007234 A MX2012007234 A MX 2012007234A MX 2012007234 A MX2012007234 A MX 2012007234A
Authority
MX
Mexico
Prior art keywords
calcipotriol monohydrate
monohydrate nanocrystals
nanocrystals
calcipotriol
prevention
Prior art date
Application number
MX2012007234A
Other languages
English (en)
Inventor
Karsten Petersson
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MX2012007234A publication Critical patent/MX2012007234A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/21Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen los nanocristales de monohidrato de calcipotriol preparados mediante el proceso de la presente, que pueden ser incorporados en una composición farmacéutica para el uso en la prevención o tratamiento de trastornos y condiciones dérmicas.
MX2012007234A 2009-12-22 2010-12-22 Nanocristales de monohidrato de calciprotiol. MX2012007234A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK2009000267 2009-12-22
US29309110P 2010-01-07 2010-01-07
PCT/DK2010/000183 WO2011076208A2 (en) 2009-12-22 2010-12-22 Calcipotriol monohydrate nanocrystals

Publications (1)

Publication Number Publication Date
MX2012007234A true MX2012007234A (es) 2012-07-30

Family

ID=43618145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007234A MX2012007234A (es) 2009-12-22 2010-12-22 Nanocristales de monohidrato de calciprotiol.

Country Status (16)

Country Link
US (2) US20130039952A1 (es)
EP (1) EP2515874B1 (es)
JP (1) JP5816194B2 (es)
CN (1) CN102770125B (es)
AU (1) AU2010335655B2 (es)
BR (1) BR112012015449B1 (es)
CA (1) CA2785253A1 (es)
ES (1) ES2523119T3 (es)
HK (1) HK1177694A1 (es)
IL (1) IL220516A (es)
MX (1) MX2012007234A (es)
NZ (1) NZ601000A (es)
PL (1) PL2515874T3 (es)
RU (1) RU2555339C2 (es)
WO (1) WO2011076208A2 (es)
ZA (1) ZA201204618B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6491658B2 (ja) * 2013-07-18 2019-03-27 マンカインド コーポレイション 熱安定性乾燥粉末医薬組成物及び方法
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
BR112019000112A2 (pt) 2016-07-05 2019-04-09 Kratos LLC partículas do grupo iva micrônicas e sub-micrônicas pré-litiadas passivadas e métodos de preparação das mesmas
WO2018183909A1 (en) * 2017-03-31 2018-10-04 Kratos LLC Precharged negative electrode material for secondary battery
CN108904445A (zh) * 2018-08-06 2018-11-30 江苏知原药业有限公司 钙泊三醇纳米悬浮液
CN109157661B (zh) * 2018-09-10 2021-09-24 南京工业大学 一种配体辅助下用氧化物silica包覆疏水性分子晶体的方法
RU2749360C1 (ru) * 2020-10-09 2021-06-09 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ лечения ладонно-подошвенного пустулеза

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315787D0 (en) * 1983-06-08 1983-07-13 Briggs J H Coolant spray
US4758432A (en) * 1984-10-15 1988-07-19 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9300763D0 (en) * 1993-01-15 1993-03-03 Leo Pharm Prod Ltd Chemical compound
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6403654B1 (en) * 2000-04-13 2002-06-11 Mariana De Oliveira Compositions for and method of treatment for psoriasis
DK1331927T3 (da) * 2000-10-27 2008-05-05 Leo Pharma As Topisk komposition der indeholder mindst et D-vitamin eller en D-vitamin analog og mindst et kosttikosteroid
CA2436574A1 (en) * 2000-12-06 2002-06-13 Pharmacia Corporation Laboratory scale milling process
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
AU2002356294A1 (en) 2002-12-13 2004-07-09 Jagotec Ag A topical nanoparticulate spironolactone formulation
DK1658263T3 (da) 2003-07-24 2010-09-27 Leo Pharma As Aminobenzophenonforbindelser
WO2005107710A2 (en) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
ATE455768T1 (de) 2004-12-13 2010-02-15 Leo Pharma As Triazolsubstituierte aminobenzophenonverbindungen
JP5612263B2 (ja) * 2005-06-01 2014-10-22 スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド ビタミン製剤
US20070154402A1 (en) * 2005-10-24 2007-07-05 Collegium Pharmaceutical, Inc. Topical Pharmaceutical Foam Composition
AU2007264418B2 (en) * 2006-06-30 2012-05-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CA2669392C (en) * 2006-11-17 2016-05-10 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
AU2007336538B2 (en) 2006-12-22 2012-04-05 Leo Pharma A/S Substituted acetophenones useful as PDE4 inhibitors
JP5501770B2 (ja) 2007-02-28 2014-05-28 レオ ファーマ アクティーゼルスカブ 新規ホスホジエステラーゼ阻害剤
WO2008128538A1 (en) 2007-04-19 2008-10-30 Leo Pharma A/S Src family kinase inhibitors
US20100189674A1 (en) 2007-05-11 2010-07-29 Sonneborn Inc. Petrolatum Having Silicone-Like Properties
MX2011006428A (es) 2008-12-19 2011-07-28 Leo Pharma As Triazolopiridinas como inhibidores de fosfodiesterasa para tratamiento de enfermedades dermicas.

Also Published As

Publication number Publication date
EP2515874B1 (en) 2014-08-20
US20140322331A1 (en) 2014-10-30
IL220516A (en) 2015-06-30
US20130039952A1 (en) 2013-02-14
RU2555339C2 (ru) 2015-07-10
EP2515874A2 (en) 2012-10-31
CN102770125A (zh) 2012-11-07
PL2515874T3 (pl) 2015-01-30
BR112012015449B1 (pt) 2021-09-28
AU2010335655B2 (en) 2015-03-05
NZ601000A (en) 2014-07-25
JP2013515019A (ja) 2013-05-02
CA2785253A1 (en) 2011-06-30
AU2010335655A1 (en) 2012-07-19
WO2011076208A3 (en) 2012-03-01
ES2523119T3 (es) 2014-11-21
RU2012130412A (ru) 2014-01-27
BR112012015449A2 (pt) 2016-03-15
JP5816194B2 (ja) 2015-11-18
HK1177694A1 (en) 2013-08-30
CN102770125B (zh) 2015-02-11
ZA201204618B (en) 2013-09-25
WO2011076208A2 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
MX2012007234A (es) Nanocristales de monohidrato de calciprotiol.
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MX2009010407A (es) Derivados fluorados de deferiprona.
IN2012DN00971A (es)
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
PL2429515T3 (pl) Nowe leki do stosowania miejscowego oparte na siarczanowanym kwasie hialuronowym jako środku aktywującym lub inhibitującym aktywność cytokin
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
PH12012501389A1 (en) Hedgehog inhibitors
EP2296665A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PREMATURE EJACULATION
PL2640364T3 (pl) Kompozycja farmaceutyczna zawierająca sól wodorowęglanową i jej zastosowanie jako leku w leczeniu i/lub profilaktyce kamicy moczowej i chorób pokrewnych
WO2011113000A8 (en) Novel ester containing compositions and methods
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
EP2480099A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES
HK1172568A1 (en) Soluble pharmaceutical forms of n,n-diaminodiphenyl sulphone for optimum use in the treatment of various diseases nn-
WO2010149658A3 (en) Pharmaceutical composition comprising gamma - butyrobetaine and meldonium
UA56130U (ru) Способ лечения и профилактики телязиоза
WO2011075605A3 (en) Hyperglycosylated interferon variants and methods of use
HU0800083D0 (en) Pharmaceutical compositions for the treatment and prevention of tumorous diseases

Legal Events

Date Code Title Description
FG Grant or registration